Access to unlicensed medicines, who should pay when they are not provided for free?
The rising cost of clinical development, license submissions, commercial product launches, and affiliate management in all countries around the world, coupled with the ethical obligation to ensure that eligible patients have access to new treatments, has led some pharmaceutical and biopharmaceutical...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-09-01
|
| Series: | Medicine Access @ Point of Care |
| Online Access: | https://doi.org/10.1177/23992026211040047 |